Symplicity renal denervation system accepted for joint FDA premarket approval
Medtronic announced the FDA and CMS have accepted the inclusion of the Symplicity™ renal denervation system for treatment-resistant hypertension in their parallel review program. This will allow CMS to begin consideration for national coverage while the FDA completes its safety and efficacy review. March 06, 2013